As of Beijing time The data is from a third-party organization and is only for reference.
For actual information, please refer to：www.eastmoney.com
Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)
Tel: +1(626)986-9880
Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK
Tel: 0044 7790 816 954
Email: marketing@medicilon.com
Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)
Postcode: 201299
Tel: +86 (21) 5859-1500 (main line)
Fax: +86 (21) 5859-6369
© 2023 Shanghai Medicilon Inc. All rights reserved Shanghai ICP No.10216606-3
Shanghai Public Network Security File No. 31011502018888 | Website Map
Business Inquiry
Global：
Email:marketing@medicilon.com
+1(626)986-9880(U.S.)
0044 7790 816 954 (Europe)
China：
Email: marketing@medicilon.com.cn
Tel: +86 (21) 5859-1500
| Disease | Type |
|---|---|
| Ocular Diseases Models | Conjunctival tissue proliferation and NV |
Diabetic retinopathy (DR) | |
Choroidal neovascularization (CNV) and subretinal fibrosis | |
Corneal neovascularization (Corneal NV) | |
Retinal neovascularization | |
Acute ocular inflammation models | |
Dry eye | |
...... |
Ophthalmic Drug Platform
Medicilon’s preclinical ophthalmic research platform has an experienced team integrating advanced drug delivery technology and analysis methodology. Equipped with state of the art devices, we can provide high-quality and efficient experimental research services, professional registration and application support and project management services for customers with ophthalmic drug development needs.
Relevant articles
marketing@medicilon.com
ABOUT
